Gilbert Harlan Daniels, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 36 | 2023 | 2309 | 2.960 |
Why?
|
Thyrotoxicosis | 8 | 2013 | 83 | 2.380 |
Why?
|
Carcinoma, Papillary, Follicular | 5 | 2016 | 60 | 1.960 |
Why?
|
Hyperthyroidism | 7 | 2023 | 292 | 1.860 |
Why?
|
Thyroiditis | 6 | 2020 | 86 | 1.670 |
Why?
|
Iodine Radioisotopes | 11 | 2023 | 1029 | 1.510 |
Why?
|
Thyroid Nodule | 11 | 2019 | 759 | 1.500 |
Why?
|
Calcitonin | 8 | 2017 | 330 | 1.410 |
Why?
|
Graves Disease | 7 | 2023 | 242 | 1.130 |
Why?
|
Adenocarcinoma, Follicular | 6 | 2021 | 325 | 0.840 |
Why?
|
Thyroidectomy | 11 | 2013 | 896 | 0.730 |
Why?
|
Thyroid Gland | 9 | 2023 | 1166 | 0.610 |
Why?
|
Carcinoma, Papillary | 8 | 2016 | 782 | 0.610 |
Why?
|
Hypothyroidism | 6 | 2009 | 663 | 0.580 |
Why?
|
Thyroxine | 8 | 2011 | 666 | 0.530 |
Why?
|
Hypoglycemic Agents | 6 | 2017 | 3107 | 0.530 |
Why?
|
Oncogene Fusion | 2 | 2021 | 81 | 0.520 |
Why?
|
Thyrotropin | 9 | 2012 | 831 | 0.480 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2014 | 358 | 0.430 |
Why?
|
Thyroid Diseases | 3 | 2013 | 384 | 0.420 |
Why?
|
Biopsy, Fine-Needle | 7 | 2014 | 1108 | 0.410 |
Why?
|
Pyrroles | 2 | 2008 | 1131 | 0.390 |
Why?
|
Ioxaglic Acid | 1 | 2011 | 29 | 0.390 |
Why?
|
Thyroiditis, Autoimmune | 1 | 2012 | 102 | 0.390 |
Why?
|
Indoles | 2 | 2008 | 1815 | 0.350 |
Why?
|
Biopsy, Needle | 5 | 2012 | 1632 | 0.340 |
Why?
|
Terminology as Topic | 1 | 2016 | 1527 | 0.320 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7399 | 0.320 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 538 | 0.310 |
Why?
|
Radiotherapy | 3 | 2013 | 1506 | 0.300 |
Why?
|
Hypopituitarism | 1 | 2008 | 247 | 0.280 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2021 | 2035 | 0.270 |
Why?
|
Lithium Compounds | 1 | 2008 | 225 | 0.270 |
Why?
|
Carotid Artery, Internal | 1 | 2008 | 433 | 0.270 |
Why?
|
Ultrasonography | 5 | 2020 | 5918 | 0.260 |
Why?
|
Endocrine System Diseases | 1 | 2008 | 251 | 0.260 |
Why?
|
Adenoma | 1 | 2016 | 2141 | 0.260 |
Why?
|
Arteriovenous Fistula | 1 | 2008 | 312 | 0.260 |
Why?
|
Thyroglobulin | 5 | 2014 | 111 | 0.250 |
Why?
|
Hyperprolactinemia | 2 | 2008 | 127 | 0.240 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2017 | 12152 | 0.240 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2021 | 341 | 0.230 |
Why?
|
Diabetes Complications | 1 | 2011 | 1341 | 0.220 |
Why?
|
Radiation Tolerance | 2 | 2015 | 476 | 0.210 |
Why?
|
Immunoglobulins, Thyroid-Stimulating | 2 | 2013 | 34 | 0.210 |
Why?
|
Mutation | 7 | 2021 | 29705 | 0.210 |
Why?
|
Radiopharmaceuticals | 3 | 2023 | 2652 | 0.200 |
Why?
|
Thyroiditis, Subacute | 1 | 2001 | 11 | 0.200 |
Why?
|
Humans | 73 | 2023 | 752341 | 0.190 |
Why?
|
Contrast Media | 2 | 2013 | 5276 | 0.190 |
Why?
|
Carcinoma, Medullary | 4 | 2011 | 115 | 0.190 |
Why?
|
Adenoma, Oxyphilic | 2 | 2021 | 147 | 0.190 |
Why?
|
Lithium Carbonate | 1 | 2001 | 180 | 0.190 |
Why?
|
Genetic Testing | 1 | 2013 | 3505 | 0.170 |
Why?
|
Amiodarone | 1 | 2001 | 218 | 0.160 |
Why?
|
Risperidone | 1 | 2000 | 380 | 0.150 |
Why?
|
Triiodothyronine | 3 | 2011 | 494 | 0.150 |
Why?
|
Female | 46 | 2017 | 386053 | 0.150 |
Why?
|
Middle Aged | 33 | 2017 | 217019 | 0.150 |
Why?
|
Antimanic Agents | 1 | 2001 | 520 | 0.150 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 842 | 0.150 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 3165 | 0.140 |
Why?
|
Pheochromocytoma | 2 | 2005 | 326 | 0.140 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 12898 | 0.140 |
Why?
|
Thyroid Function Tests | 2 | 2013 | 290 | 0.130 |
Why?
|
Male | 39 | 2017 | 354881 | 0.130 |
Why?
|
Virus Diseases | 1 | 2001 | 720 | 0.120 |
Why?
|
Cell Differentiation | 3 | 2019 | 11422 | 0.120 |
Why?
|
Granuloma, Foreign-Body | 1 | 1995 | 42 | 0.120 |
Why?
|
Hyperplasia | 2 | 2017 | 1154 | 0.120 |
Why?
|
Thyroid Hormones | 2 | 2008 | 391 | 0.120 |
Why?
|
Amylases | 1 | 2014 | 169 | 0.120 |
Why?
|
Aged | 26 | 2016 | 166562 | 0.120 |
Why?
|
Pentagastrin | 2 | 2011 | 17 | 0.120 |
Why?
|
Carcinoma | 3 | 2015 | 2340 | 0.120 |
Why?
|
Polytetrafluoroethylene | 1 | 1995 | 244 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 3177 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 17648 | 0.110 |
Why?
|
Compartment Syndromes | 1 | 1995 | 155 | 0.110 |
Why?
|
Adult | 26 | 2014 | 216913 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3678 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2019 | 560 | 0.110 |
Why?
|
Lipase | 1 | 2014 | 325 | 0.100 |
Why?
|
Ferrosoferric Oxide | 1 | 2013 | 348 | 0.100 |
Why?
|
Interferon-beta | 1 | 2013 | 340 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1767 | 0.100 |
Why?
|
Receptors, Thyrotropin | 1 | 2011 | 45 | 0.090 |
Why?
|
Double-Blind Method | 5 | 2017 | 12326 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2269 | 0.090 |
Why?
|
Receptors, Glucagon | 1 | 2011 | 90 | 0.090 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 2 | 2011 | 40 | 0.090 |
Why?
|
Adrenal Glands | 1 | 2013 | 556 | 0.090 |
Why?
|
Iodine | 1 | 2013 | 290 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1875 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10797 | 0.090 |
Why?
|
Adenocarcinoma | 3 | 2020 | 6306 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2782 | 0.090 |
Why?
|
Neck Dissection | 1 | 2011 | 200 | 0.080 |
Why?
|
Pituitary Function Tests | 1 | 2008 | 24 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2008 | 13553 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2013 | 14586 | 0.080 |
Why?
|
Obesity | 1 | 2011 | 12806 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3585 | 0.080 |
Why?
|
Prostheses and Implants | 1 | 1995 | 1272 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4271 | 0.070 |
Why?
|
Linear Models | 2 | 2015 | 5858 | 0.070 |
Why?
|
Sex Factors | 4 | 2015 | 10455 | 0.070 |
Why?
|
Antipsychotic Agents | 1 | 2000 | 3050 | 0.070 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2093 | 0.070 |
Why?
|
Adrenal Insufficiency | 1 | 2008 | 192 | 0.070 |
Why?
|
Adipose Tissue, Brown | 1 | 2012 | 757 | 0.070 |
Why?
|
Canada | 1 | 2011 | 2103 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4110 | 0.070 |
Why?
|
SEER Program | 2 | 2014 | 1520 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2017 | 39079 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 1486 | 0.060 |
Why?
|
Reference Values | 3 | 2013 | 4897 | 0.060 |
Why?
|
Autoantibodies | 1 | 2013 | 2075 | 0.060 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2007 | 218 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2014 | 58300 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2012 | 6781 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2016 | 15621 | 0.060 |
Why?
|
History, 20th Century | 1 | 2013 | 2759 | 0.060 |
Why?
|
Pregnancy Complications | 1 | 1999 | 2921 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2013 | 19894 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2005 | 221 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2013 | 79127 | 0.060 |
Why?
|
Lipid Peroxides | 1 | 2023 | 69 | 0.060 |
Why?
|
Oxyphil Cells | 1 | 2023 | 57 | 0.050 |
Why?
|
Angiography | 1 | 2008 | 1607 | 0.050 |
Why?
|
Fermentation | 1 | 2023 | 146 | 0.050 |
Why?
|
Lymphatic Metastasis | 4 | 2012 | 2924 | 0.050 |
Why?
|
Calcium | 2 | 2013 | 5699 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2649 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10177 | 0.050 |
Why?
|
Quinazolines | 1 | 2008 | 1355 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2016 | 64245 | 0.050 |
Why?
|
Iodide Peroxidase | 1 | 2003 | 294 | 0.050 |
Why?
|
Body Mass Index | 2 | 2017 | 12796 | 0.050 |
Why?
|
Young Adult | 5 | 2014 | 57629 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3209 | 0.050 |
Why?
|
Point Mutation | 1 | 2005 | 1591 | 0.040 |
Why?
|
Phosphotransferases | 1 | 2021 | 306 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2013 | 3369 | 0.040 |
Why?
|
Bone Density | 1 | 2013 | 3498 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15130 | 0.040 |
Why?
|
Osmolar Concentration | 1 | 2000 | 664 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20348 | 0.040 |
Why?
|
Vitamin D | 1 | 2013 | 3273 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2008 | 2146 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2011 | 11064 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2680 | 0.040 |
Why?
|
Prolactin | 1 | 2000 | 631 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 131 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 29327 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2012 | 9207 | 0.040 |
Why?
|
Clozapine | 1 | 2000 | 500 | 0.040 |
Why?
|
Research Report | 1 | 2020 | 366 | 0.040 |
Why?
|
Chorionic Gonadotropin | 1 | 1999 | 455 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2002 | 3474 | 0.030 |
Why?
|
Goiter, Nodular | 1 | 1996 | 28 | 0.030 |
Why?
|
Time Factors | 3 | 2012 | 39854 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4861 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3463 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6413 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5288 | 0.030 |
Why?
|
Risk | 2 | 2004 | 9613 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1999 | 1978 | 0.030 |
Why?
|
Pakistan | 1 | 1995 | 298 | 0.030 |
Why?
|
Pregnancy | 2 | 2011 | 29439 | 0.030 |
Why?
|
Methimazole | 1 | 2013 | 41 | 0.030 |
Why?
|
United States | 6 | 2014 | 71442 | 0.030 |
Why?
|
Propylthiouracil | 1 | 2013 | 68 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 35916 | 0.030 |
Why?
|
Mass Screening | 2 | 2007 | 5397 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2013 | 70 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 309 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 740 | 0.030 |
Why?
|
Whole Body Imaging | 1 | 2014 | 278 | 0.030 |
Why?
|
Health Status | 1 | 2006 | 4050 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 4274 | 0.020 |
Why?
|
Postpartum Period | 1 | 1999 | 1160 | 0.020 |
Why?
|
Barium Sulfate | 1 | 2012 | 176 | 0.020 |
Why?
|
Iopamidol | 1 | 2012 | 186 | 0.020 |
Why?
|
Vocal Cord Paralysis | 1 | 1995 | 269 | 0.020 |
Why?
|
Neoplasms | 2 | 2017 | 21808 | 0.020 |
Why?
|
Ablation Techniques | 1 | 2013 | 246 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2002 | 8538 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2011 | 335 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2001 | 6482 | 0.020 |
Why?
|
Pain | 2 | 2006 | 4988 | 0.020 |
Why?
|
Prevalence | 3 | 2014 | 15506 | 0.020 |
Why?
|
Cytodiagnosis | 1 | 2013 | 431 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2007 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3034 | 0.020 |
Why?
|
Adolescent | 5 | 2014 | 86765 | 0.020 |
Why?
|
Child | 3 | 2013 | 78998 | 0.020 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2011 | 239 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1175 | 0.020 |
Why?
|
Incidental Findings | 1 | 2013 | 689 | 0.020 |
Why?
|
Fasting | 1 | 2014 | 1590 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2012 | 504 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2006 | 548 | 0.020 |
Why?
|
Drainage | 1 | 2013 | 1153 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 1176 | 0.020 |
Why?
|
Pancreatitis | 1 | 2014 | 1098 | 0.020 |
Why?
|
Melanoma | 1 | 2006 | 5620 | 0.020 |
Why?
|
Vanilmandelic Acid | 1 | 2005 | 17 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5726 | 0.020 |
Why?
|
Metanephrine | 1 | 2005 | 25 | 0.020 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 2005 | 25 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4601 | 0.020 |
Why?
|
Catecholamines | 1 | 2005 | 385 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2005 | 757 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2010 | 1774 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11266 | 0.010 |
Why?
|
Ultrasonography, Doppler | 1 | 2007 | 463 | 0.010 |
Why?
|
Preoperative Care | 1 | 2013 | 2232 | 0.010 |
Why?
|
Cohort Studies | 3 | 2014 | 40984 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 1990 | 917 | 0.010 |
Why?
|
Quality of Life | 1 | 2006 | 13153 | 0.010 |
Why?
|
Biopsy | 1 | 1996 | 6743 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7211 | 0.010 |
Why?
|
Codon | 1 | 2005 | 601 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1465 | 0.010 |
Why?
|
Neck | 2 | 2002 | 724 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6234 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 1993 | 0.010 |
Why?
|
Risk Assessment | 3 | 2012 | 23783 | 0.010 |
Why?
|
Incidence | 2 | 2014 | 21158 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1996 | 3502 | 0.010 |
Why?
|
Sex Distribution | 1 | 2007 | 2290 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2335 | 0.010 |
Why?
|
Age Distribution | 1 | 2007 | 2883 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8707 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6372 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12746 | 0.010 |
Why?
|
Kidney | 1 | 2014 | 6983 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1992 | 2252 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12137 | 0.010 |
Why?
|
Pedigree | 1 | 2005 | 4573 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6116 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 6501 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13277 | 0.010 |
Why?
|
Cysts | 1 | 2002 | 681 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6509 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18297 | 0.010 |
Why?
|
Survivors | 1 | 2006 | 2324 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2016 | 11830 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 6964 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2005 | 4717 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 21841 | 0.010 |
Why?
|
Stroke | 1 | 2016 | 9879 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2007 | 11007 | 0.010 |
Why?
|
Prospective Studies | 2 | 2013 | 53807 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15437 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15676 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1990 | 572 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1996 | 1247 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1990 | 237 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 41659 | 0.010 |
Why?
|
Animals | 1 | 2001 | 166802 | 0.000 |
Why?
|
Luminescent Measurements | 1 | 1990 | 375 | 0.000 |
Why?
|
Immunoassay | 1 | 1990 | 746 | 0.000 |
Why?
|